GeoVax Q3 net loss widens to $8.4M; Phase 2 COVID vaccine enrollment completed

GeoVax Labs, Inc.

Net loss $8.4M ($0.32/share) vs $3.97M ($0.17/share) in Q3 2022; cash $12.7M at Sep 30 vs $27.6M at Dec 31.
R&D expenses rose to $6.9M from $2.7M, driven by clinical trial costs for GEO-CM04S1 and Gedeptin.
Completed enrollment in Phase 2 trial of GEO-CM04S1 as a booster; initial data readout expected soon.
Signed multi-product license with ProBioGen for AGE1.CR.pIX suspension cell line to enhance MVA vaccine manufacturing.
Received U.S. patent allowances for Ebola, Marburg, Malaria, and HIV vaccines.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeoVax Labs, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 8, 2023, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended September 30, 2023.

View on SEC.gov

4 earnings releases filed in the last 30 days. Browse all earnings releases →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-031145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.